Lineage Q3 2024 Earnings Report
Key Takeaways
Lineage Cell Therapeutics reported a net loss attributable to Lineage of $3.0 million, or $0.02 per share, for the three months ended September 30, 2024. Total revenues for the quarter were $3.8 million, an increase of approximately $2.5 million compared to the same period in 2023. Cash, cash equivalents, and marketable securities totaled $32.7 million as of September 30, 2024.
OpRegenĀ® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA
ReSonanceā¢ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop
Lineage was added to 2024 Russell 3000Ā® Index
Total revenues for the three months ended September 30, 2024 were $3.8 million
Lineage
Lineage
Forward Guidance
Cash, cash equivalents, and marketable securities of $32.7 million as of September 30, 2024 is expected to support planned operations into Q1 2026.